|
시장보고서
상품코드
1983197
OTC 의약품 시장 : 제품 유형별, 유통 채널별, 지역별Over the Counter Drugs Market, By Product Type, By Distribution Channel, By Geography |
||||||
OTC 의약품(시판약) 시장은 2026년에 586억 5,000만 달러로 추정되고 있으며, 2033년까지 988억 7,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 8.54%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 586억 5,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2032년) | 8.54% | 예측 금액(2033년) | 988억 7,000만 달러 |
OTC(Over-the-counter) 의약품은 의료인의 처방전 없이 소비자에게 직접 판매되는 의약품을 말합니다. 이는 약사가 처방전 없이 판매할 수 있도록 법적으로 허용되어 있기 때문입니다. OTC 의약품은 라벨의 지시와 의료진의 지시에 따라 사용하면 안전하고 효과적입니다. OTC 의약품은 다양한 질병과 그 증상을 치료하고, 의사에게 진찰을 받는 비용 없이 쉽게 질병을 치료할 수 있도록 도와줍니다.
시장 역학
질병 부담 증가, OTC 의약품에 대한 수요 증가, 셀프 메디케이션 증가 추세, COVID-19 확산, 제약사들이 처방약에서 OTC 의약품으로 전환하는 추세는 예측 기간 중 세계 OTC 의약품 시장의 성장을 촉진할 것으로 예상되는 주요 요인입니다.
2022년 6월, 글렌마크 파마슈티컬스는 미국 웍하트사로부터 특정 OTC 의약품에 대한 제네릭 의약품을 승인받았습니다. 이 회사는 성명서에서 이번 인수에는 위 및 장 궤양 치료 및 예방에 사용되는 파모티딘 정제(10mg 및 20mg)에 대한 승인된 간이 신약 신청(ANDA)이 포함되어 있다고 밝혔습니다.
2020년 7월, 노바티스는 백신이나 근본적인 치료제가 없는 상황에서 매우 중요한 필요성이 대두되고 있는 저소득 및 중저소득 국가의 환자들이 COVID-19의 주요 증상을 치료할 수 있는 합리적인 가격의 의약품을 이용할 수 있도록 지원하기 위한 새로운 구상을 발표했습니다. 노바티스의 COVID-19 관련 제품 포트폴리오에는 15개의 제네릭 및 OTC 의약품이 포함되어 있으며, 저소득 및 중저소득 국가의 COVID-19 환자 치료라는 긴급하고 미충족된 수요를 충족시키고 있습니다.
이 보고서의 주요 특징
- 세계의 일반의약품(OTC) 시장에 대해 조사 분석했으며, 2021년을 기준 연도로 하여 예측 기간(2022-2028년) 시장 규모와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
- 또한 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트을 제공합니다.
- 세계 OTC 의약품 시장의 주요 기업 개요을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등의 매개 변수를 기반으로 정리하여 수록했습니다.
- 이 보고서의 인사이트을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 OTC 의약품 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 OTC 의약품 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 OTC 의약품 시장 : 제품 유형별(2026-2033년)
제5장 세계의 OTC 의약품 시장 : 유통 채널별(2026-2033년)
제6장 세계의 OTC 의약품 시장 : 지역별(2026-2033년)
제7장 경쟁 구도
제8장 애널리스트의 제안
제9장 참고 문헌 및 분석 방법
KSA 26.04.20Over The Counter Drugs Market is estimated to be valued at USD 58.65 Bn in 2026 and is expected to reach USD 98.87 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.54% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 58.65 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.54% | 2033 Value Projection: | USD 98.87 Bn |
Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a requirement for a prescription (without a prescription) from the healthcare professional, as they are legally allowed to be sold by pharmacists without a prescription. When people follow the directions on the label and as directed by a health care professional, over-the-counter medicines are both safe and effective. Over-the-counter drugs treat a variety of illnesses and their symptoms and help cure some diseases simply and without the cost of seeing a doctor.
Market Dynamics
Increase in disease burden, increase in demand for OTC drugs, rising trend of self-medication, the outbreak of COVID-19, and inclination of pharma companies toward OTC drugs from RX drugs are major factors expected to drive growth of the global during the counter drugs market over the forecast period.
In June 2022, Glenmark Pharmaceuticals Ltd. acquired the approved generic versions of certain over-the-counter drugs from Wockhardt Ltd. in the U.S. The acquisition includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets, 10 mg and 20 mg used to treat and prevent ulcers in the stomach and intestine, the company said in a statement.
In July 2020, Novartis announced a new initiative to help patients in low-income and lower-middle-income countries access affordable medicines to treat the major symptoms of COVID-19, a critical need in the absence of a vaccine or curative treatment. The Novartis COVID-19 portfolio includes 15 generic and OTC medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms.
Key features of the study
- This report provides in-depth analysis of the global over the counter drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global over the counter drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., Perrigo Company PLC, GlaxoSmithKline PLC, Mylan NV, Bayer AG, Reckitt Benckiser Group PLC, Johnson and Johnson, Sanofi, and Takeda Pharmaceutical Company Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global over the counter drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global over the counter drugs market.
Market Segmentation
- By Product Type
- Cough, Cold, and Flu Products
- Analgesics
- Dermatology Products
- Gastrointestinal Products
- Vitamins
- Mineral and Supplements (VMS)
- Weight-loss/Dietary Products
- Ophthalmic Products
- Sleeping Aids
- Other Product Types
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacy
- Other Distribution Channels
- By Regional Insights:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Perrigo Company PLC
- GlaxoSmithKline PLC
- Mylan NV
- Bayer AG
- Reckitt Benckiser Group PLC
- Johnson and Johnson
- Sanofi
- Takeda Pharmaceutical Company Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- PEST Analysis
- PORTER's Five Forces Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Over the Counter Drugs Market, By Product Type, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Cough, Cold, and Flu Products
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Analgesics
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Dermatology Products
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Gastrointestinal Products
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Vitamins
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Mineral and Supplements (VMS)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Weight-loss/Dietary Products
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Ophthalmic Products
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Sleeping Aids
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Other Product Types
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Over the Counter Drugs Market, By Distribution Channel, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Online Pharmacy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Other Distribution Channels
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Over the Counter Drugs Market, By Region, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- South Africa
- North Africa
- Central Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3x3 Matrix)
- Company Profiles
- Pfizer Inc.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Perrigo Company PLC
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- GlaxoSmithKline PLC
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Mylan NV
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Bayer AG
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Reckitt Benckiser Group PLC
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Johnson and Johnson
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Sanofi
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Takeda Pharmaceutical Company Ltd.
- Company Overview
- Product Type Portfolio
- Recent Developments/Updates
- Pfizer Inc.
8. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
9. Section
- References
- Research Methodology
- About Us and Sales Contact
